The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation

International Journal of Molecular Sciences

Volumn 13, Issue 10, 2012, Pages 13737-13747

  Gu, Ai Di ^a   Zeng, Mu Sheng ^b   Qian, Chao Nan ^c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Epstein Barr virus; Infection; Nasopharyngeal carcinoma; Tumorigenesis

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY DETECTION; BIOACCUMULATION; CANCER GROWTH; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NASOPHARYNX CARCINOMA; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; VIRAL CLEARANCE; VIROGENESIS; VIRUS ACTIVATION; VIRUS LOAD; VIRUS TRANSMISSION; ANIMAL; CARCINOGENESIS; COMPLICATION; DISEASE MODEL; EPSTEIN-BARR VIRUS INFECTIONS; IMMUNOLOGY; METABOLISM; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; VIROLOGY;

ANIMALS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; VIRAL VACCINES;

EID: 84870652905     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131013737     Document Type: Review

References (68)

1. Rivers, T.M. Viruses and Koch's Postulates. J. Bacteriol. 1937, 33, 1-12.
2. Fouchier, R.A.; Kuiken, T.; Schutten, M.; van Amerongen, G.; van Doornum, G.J.; van den Hoogen, B.G.; Peiris, M.; Lim, W.; Stohr, K.; Osterhaus, A.D. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003, 423, 240.
3. Epstein, M.A.; Achong, B.G.; Barr, Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 1, 702-703.
4. Dane, D.S.; Cameron, C.H.; Briggs, M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970, 1, 695-698.
5. Poiesz, B.J.; Ruscetti, F.W.; Gazdar, A.F.; Bunn, P.A.; Minna, J.D.; Gallo, R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl. Acad. Sci. USA 1980, 77, 7415-7419.
6. Chang, Y.; Cesarman, E.; Pessin, M.S.; Lee, F.; Culpepper, J.; Knowles, D.M.; Moore, P.S. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994, 266, 1865-1869.
7. Rickinson, A.B.; Kieff, E. Epstein-Barr Virus, 4th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; pp. 2575-2627.
8. Yao, Q.Y.; Rickinson, A.B.; Epstein, M.A. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer 1985, 35, 35-42.
9. Henle, G.; Henle, W.; Diehl, V. Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc. Natl. Acad. Sci. USA 1968, 59, 94-101.
10. Raab-Traub, N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 2002, 12, 431-441.
11. Old, L.J.; Boyse, E.A.; Oettgen, H.F.; Harven, E.D.; Geering, G.; Williamson, B.; Clifford, P. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc. Natl. Acad. Sci. USA 1966, 56, 1699-1704.
12. De The, G. Chapter 4: Sero Epidemiology of EBV and Associated Malignancies. In Epstein-Barr Virus: Latency and Transformation, 1st ed.; Caister Academic Press: London, UK, 2005.
13. Cao, S.M.; Simons, M.J.; Qian, C.N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 2011, 30, 114-119.
14. Chien, Y.C.; Chen, J.Y.; Liu, M.Y.; Yang, H.I.; Hsu, M.M.; Chen, C.J.; Yang, C.S. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 2001, 345, 1877-1882.
15. Gu, A.D.; Xie, Y.B.; Mo, H.Y.; Jia, W.H.; Li, M.Y.; Li, M.; Chen, L.Z.; Feng, Q.S.; Liu, Q.; Qian, C.N. et al. Antibodies against Epstein-Barr virus gp78 antigen: A novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. J. Gen. Virol. 2008, 89, 1152-1158.
16. Ji, M.F.; Wang, D.K.; Yu, Y.L.; Guo, Y.Q.; Liang, J.S.; Cheng, W.M.; Zong, Y.S.; Chan, K.H.; Ng, S.P.; Wei, W.I. et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br. J. Cancer 2007, 96, 623-630.
17. Wee, J.T.; Ha, T.C.; Loong, S.L.; Qian, C.N. Is nasopharyngeal cancer really a "Cantonese cancer"? Chin. J. Cancer 2010, 29, 517-526.
18. Lo, K.W.; To, K.F.; Huang, D.P. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5, 423-428.
19. Chang, E.T.; Adami, H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1765-1777.
20. Pickard, A.; Chen, C.J.; Diehl, S.R.; Liu, M.Y.; Cheng, Y.J.; Hsu, W.L.; Sun, B.; Hsu, M.M.; Chen, I.H.; Chen, J.Y. et al. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int. J. Cancer 2004, 111, 117-123.
21. Gu, A.D.; Lu, L.X.; Xie, Y.B.; Chen, L.Z.; Feng, Q.S.; Kang, T.; Jia, W.H.; Zeng, Y.X. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J. Transl. Med. 2009, 7, 73.
22. Xu, F.H.; Xiong, D.; Xu, Y.F.; Cao, S.M.; Xue, W.Q.; Qin, H.D.; Liu, W.S.; Cao, J.Y.; Zhang, Y.; Feng, Q.S. et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and epstein-barr virus activation. J. Natl. Cancer Inst. 104, 1396-1410.
23. Feng, B.J.; Huang, W.; Shugart, Y.Y.; Lee, M.K.; Zhang, F.; Xia, J.C.; Wang, H.Y.; Huang, T.B.; Jian, S.W.; Huang, P. et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet. 2002, 31, 395-399.
24. Hu, L.F.; Qiu, Q.H.; Fu, S.M.; Sun, D.; Magnusson, K.; He, B.; Lindblom, A.; Ernberg, I. A genome-wide scan suggests a susceptibility locus on 5p 13 for nasopharyngeal carcinoma. Eur. J. Hum. Genet. 2008, 16, 343-349.
25. Raab-Traub, N.; Flynn, K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47, 883-889.
26. Kintner, C.R.; Sugden, B. The structure of the termini of the DNA of Epstein-Barr virus. Cell 1979, 17, 661-671.
27. Moody, C.A.; Scott, R.S.; Su, T.; Sixbey, J.W. Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence. J. Virol. 2003, 77, 8555-8561.
28. Wu, H.C.; Lin, Y.J.; Lee, J.J.; Liu, Y.J.; Liang, S.T.; Peng, Y.; Chiu, Y.W.; Wu, C.W.; Lin, C.T. Functional analysis of EBV in nasopharyngeal carcinoma cells. Lab. Invest. 2003, 83, 797-812.
29. Pathmanathan, R.; Prasad, U.; Sadler, R.; Flynn, K.; Raab-Traub, N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995, 333, 693-698.
30. Lin, C.T.; Dee, A.N.; Chen, W.; Chan, W.Y. Association of Epstein-Barr virus, human papilloma virus, and cytomegalovirus with nine nasopharyngeal carcinoma cell lines. Lab. Invest. 1994, 71, 731-736.
31. Lin, C.T.; Lin, C.R.; Tan, G.K.; Chen, W.; Dee, A.N.; Chan, W.Y. The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. Am. J. Pathol. 1997, 150, 1745-1756.
32. Niedobitek, G.; Herbst, H.; Stein, H. Epstein-Barr virus/complement receptor and epithelial cells. Lancet 1989, 2, 110.
33. Sam, C.K.; Brooks, L.A.; Niedobitek, G.; Young, L.S.; Prasad, U.; Rickinson, A.B. Analysis of Epstein-Barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma. Int. J. Cancer 1993, 53, 957-962.
34. Dickens, P.; Srivastava, G.; Loke, S.L.; Chan, C.W.; Liu, Y.T. Epstein-Barr virus DNA in nasopharyngeal carcinomas from Chinese patients in Hong Kong. J. Clin. Pathol. 1992, 45, 396-397.
35. Adham, M.; Kurniawan, A.N.; Muhtadi, A.I.; Roezin, A.; Hermani, B.; Gondhowiardjo, S.; Tan, I.B.; Middeldorp, J.M. Nasopharyngeal carcinoma in Indonesia: Epidemiology, incidence, signs, and symptoms at presentation. Chin. J. Cancer 2012, 31, 185-196.
36. Huang, B.; Huang, D.; Wu, Q. The examination of EBV-DNase gene fragment in the paraffin embedded NPC, pre-cancerous and high risk population nasopharyngeal tissues. Zhonghua Zhongliu Zazhi 1998, 20, 251-253.
37. Zong, Y.; Zhang, J.; Li, Z.; Chen, G.; Rong, Z.; Wu, W. Epstein-Barr virus infection in nasopharyngeal lymphoid hyperplasia. Chin. Med. J. (Engl.) 1999, 112, 845-849.
38. Lo, K.W.; Huang, D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 2002, 12, 451-462.
39. Chan, A.S.; To, K.F.; Lo, K.W.; Ding, M.; Li, X.; Johnson, P.; Huang, D.P. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int. J. Cancer 2002, 102, 300-303.
40. Song, L.B.; Zeng, M.S.; Liao, W.T.; Zhang, L.; Mo, H.Y.; Liu, W.L.; Shao, J.Y.; Wu, Q.L.; Li, M.Z.; Xia, Y.F. et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66, 6225-6232.
41. Wang, D.; Liebowitz, D.; Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43, 831-840.
42. Baichwal, V.R.; Sugden, B. Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988, 2, 461-467.
43. Wilson, J.B.; Weinberg, W.; Johnson, R.; Yuspa, S.; Levine, A.J. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990, 61, 1315-1327.
44. Busson, P.; Keryer, C.; Ooka, T.; Corbex, M. EBV-associated nasopharyngeal carcinomas: From epidemiology to virus-targeting strategies. Trends Microbiol. 2004, 12, 356-360.
45. Dolcetti, R.; Menezes, J. Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: New immunobiological and molecular insights on a long-standing etiopathogenic association. Adv. Cancer Res. 2003, 87, 127-157.
46. Kong, Q.L.; Hu, L.J.; Cao, J.Y.; Huang, Y.J.; Xu, L.H.; Liang, Y.; Xiong, D.; Guan, S.; Guo, B.H.; Mai, H.Q. et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 2010, 6, e1000940.
47. Kondo, S.; Wakisaka, N.; Muramatsu, M.; Zen, Y.; Endo, K.; Murono, S.; Sugimoto, H.; Yamaoka, S.; Pagano, J.S.; Yoshizaki, T. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J. Virol. 2011, 85, 11255-11264.
48. Eliopoulos, A.G.; Gallagher, N.J.; Blake, S.M.; Dawson, C.W.; Young, L.S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 1999, 274, 16085-16096.
49. Huen, D.S.; Henderson, S.A.; Croom-Carter, D.; Rowe, M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995, 10, 549-560.
50. Dawson, C.W.; Port, R.J.; Young, L.S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin. Cancer Biol. 22, 144-153.
51. Li, Q.X.; Young, L.S.; Niedobitek, G.; Dawson, C.W.; Birkenbach, M.; Wang, F.; Rickinson, A.B. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 1992, 356, 347-350.
52. Tomei, L.D.; Noyes, I.; Blocker, D.; Holliday, J.; Glaser, R. Phorbol ester and Epstein-Barr virus dependent transformation of normal primary human skin epithelial cells. Nature 1987, 329, 73-75.
53. Honda, S.; Fujioka, T.; Tokieda, M.; Satoh, R.; Nishizono, A.; Nasu, M. Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res. 1998, 58, 4255-4259.
54. Chisari, F.V. Hepatitis B virus transgenic mice: Models of viral immunobiology and pathogenesis. Curr. Top Microbiol. Immunol. 1996, 206, 149-173.
55. Islas-Ohlmayer, M.; Padgett-Thomas, A.; Domiati-Saad, R.; Melkus, M.W.; Cravens, P.D.; Martin Mdel, P.; Netto, G.; Garcia, J.V. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J. Virol. 2004, 78, 13891-13900.
56. Yajima, M.; Imadome, K.; Nakagawa, A.; Watanabe, S.; Terashima, K.; Nakamura, H.; Ito, M.; Shimizu, N.; Honda, M.; Yamamoto, N. et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J. Infect. Dis. 2008, 198, 673-682.
57. Shope, T.; Dechairo, D.; Miller, G. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc. Natl. Acad. Sci. USA 1973, 70, 2487-2491.
58. Epstein, M.A.; Rabin, H.; Ball, G.; Rickinson, A.B.; Jarvis, J.; Melendez, L.V. Pilot experiments with EB virus in owl monkeys (Aotus trivirgatus). II. EB virus in a cell line from an animal with reticuloproliferative disease. Int. J. Cancer 1973, 12, 319-332.
59. Moghaddam, A.; Rosenzweig, M.; Lee-Parritz, D.; Annis, B.; Johnson, R.P.; Wang, F. An animal model for acute and persistent Epstein-Barr virus infection. Science 1997, 276, 2030-2033.
60. Rivailler, P.; Carville, A.; Kaur, A.; Rao, P.; Quink, C.; Kutok, J.L.; Westmoreland, S.; Klumpp, S.; Simon, M.; Aster, J.C. et al. Experimental rhesus lymphocryptovirus infection in immunosuppressed macaques: An animal model for Epstein-Barr virus pathogenesis in the immunosuppressed host. Blood 2004, 104, 1482-1489.
61. Tarakanova, V.L.; Suarez, F.; Tibbetts, S.A.; Jacoby, M.A.; Weck, K.E.; Hess, J.L.; Speck, S.H.; Virgin, H.W., IV. Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient mice. J. Virol. 2005, 79, 14668-14679.
62. Kutok, J.L.; Klumpp, S.; Simon, M.; MacKey, J.J.; Nguyen, V.; Middeldorp, J.M.; Aster, J.C.; Wang, F. Molecular evidence for rhesus lymphocryptovirus infection of epithelial cells in immunosuppressed rhesus macaques. J. Virol. 2004, 78, 3455-3461.
63. Chang, M.H.; Chen, C.J.; Lai, M.S.; Hsu, H.M.; Wu, T.C.; Kong, M.S.; Liang, D.C.; Shau, W.Y.; Chen, D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997, 336, 1855-1859.
64. Harper, D.M.; Franco, E.L.; Wheeler, C.M.; Moscicki, A.B.; Romanowski, B.; Roteli-Martins, C.M.; Jenkins, D.; Schuind, A.; Costa Clemens, S.A.; Dubin, G. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006, 367, 1247-1255.
65. Epstein, M.A.; Morgan, A.J.; Finerty, S.; Randle, B.J.; Kirkwood, J.K. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 1985, 318, 287-289.
66. Gu, S.Y.; Huang, T.M.; Ruan, L.; Miao, Y.H.; Lu, H.; Chu, C.M.; Motz, M.; Wolf, H. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand 1995, 84, 171-177.
67. Sokal, E.M.; Hoppenbrouwers, K.; Vandermeulen, C.; Moutschen, M.; Léonard, P.; Moreels, A.; Haumont, M.; Bollen, A.; Smets, F.; Denis, M. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J. Infect. Dis. 2007, 196, 1749-1753.
68. Butel, J.S. Viral carcinogenesis: Revelation of molecular mechanisms and etiology of human disease. Carcinogenesis 2000, 21, 405-426.